CTOs on the Move


 
M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.m2gen.com
  • P.O. Box 5519
    Hudson, FL USA 34667
  • Phone: 813.384.5624

Executives

Name Title Contact Details
Daniel Elgort
Chief Data and Analytics Officer Profile
Karen Gispanski
Chief Information Security Officer Profile

Jobs

Chief Information Security Officer

M2Gen Remote
M2Gen is seeking a strong CISO to establish, develop, and grow our information security and privacy practice. Working closely with the CTO, executive leadership, and the broader organization, the ideal candidate brings in-depth knowledge of security focused software construction, security and privacy policy development and practice, solid understanding of ...

Similar Companies

Limelight Bio

Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA

Cue

Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.

Puget Sound Kidney Centers

Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micromet

Micromet, Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.